KITOV PHARMA LT/S (KTOV) Rating Increased to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of KITOV PHARMA LT/S (NASDAQ:KTOV) from a sell rating to a hold rating in a research report report published on Tuesday, Zacks.com reports.

According to Zacks, “Kitov Pharmaceuticals Holdings Ltd. is a pharmaceutical company which focused on the development of therapeutic candidates. The company’s product candidate consists of KIT-302, is formulated for treatment of pain caused by osteoarthritis and hypertension, which can be pre-existing or caused by the treatment for OA. Kitov Pharmaceuticals Holdings Ltd. is based in Jerusalem, Israel. “

Separately, ValuEngine cut shares of KITOV PHARMA LT/S from a hold rating to a sell rating in a research note on Tuesday, April 16th.

NASDAQ KTOV traded down $0.02 on Tuesday, reaching $1.02. 72,925 shares of the stock were exchanged, compared to its average volume of 199,107. KITOV PHARMA LT/S has a one year low of $0.56 and a one year high of $3.81. The stock has a market cap of $16.15 million, a price-to-earnings ratio of 2.62 and a beta of 4.26.

A hedge fund recently raised its stake in KITOV PHARMA LT/S stock. Virtu Financial LLC raised its stake in shares of KITOV PHARMA LT/S (NASDAQ:KTOV) by 70.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,898 shares of the company’s stock after buying an additional 16,069 shares during the quarter. Virtu Financial LLC owned about 0.25% of KITOV PHARMA LT/S worth $47,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 1.53% of the stock is currently owned by institutional investors and hedge funds.

About KITOV PHARMA LT/S

Kitov Pharma Ltd, through its subsidiaries, operates as a development stage biopharmaceutical company in Israel. It develops combination drugs for the simultaneous treatment of pain caused by osteoarthritis and hypertension. The company's lead drug candidate is KIT-302, a fixed dosage combination product based on the generic drugs celecoxib and amlodipine besylate that has completed its Phase III clinical study.

Read More: What are retained earnings?

Get a free copy of the Zacks research report on KITOV PHARMA LT/S (KTOV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for KITOV PHARMA LT/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KITOV PHARMA LT/S and related companies with MarketBeat.com's FREE daily email newsletter.